Structural insight into allosteric modulation of protease-activated receptor 2

Autor: Louis Leong, Benjamin Tehan, Dean G. Brown, Dawn M. Troast, Giles A. Brown, Nils-Olov Hermansson, Peter E. Thornton, Cédric Fiez-Vandal, Holly H. Soutter, Oliver Schlenker, Fiona H. Marshall, Robert M. Cooke, Arjan Snijder, Karl Edman, Christoph Grebner, Giselle R. Wiggin, A.S. Dore, Stefan Geschwindner, Andrei Zhukov, Birte Aggeler, Christoph E. Dumelin, Niek Dekker, Patrik Johansson, Robert K. Y. Cheng, Mathieu Rappas, Ali Jazayeri, Linda Sundström, Rudi Prihandoko
Rok vydání: 2017
Předmět:
Zdroj: Nature. 545:112-115
ISSN: 1476-4687
0028-0836
DOI: 10.1038/nature22309
Popis: Crystal structures of protease-activated receptor 2 (PAR2) in complex with two different antagonist ligands and with a blocking antibody reveal binding sites that are distinct from those found on PAR1, offering new leads for structure-based drug design. Protease-activated receptors (PARs) are a family of G-protein-coupled receptors (GPCRs) with roles in diverse diseases, such as neuroinflammation and cancer, and are considered important target for drug discovery. Here, Fiona Marshall and colleagues have determined three crystal structures of PAR2 in complex with two different antagonists and a blocking antibody, respectively. The antagonists bind to distinct allosteric sites on the receptor and these binding sites are different to the one previously found on PAR1. Therefore this family of GPCRs can be inhibited by a number of different allosteric mechanisms, offering new leads for structure-based drug design. Protease-activated receptors (PARs) are a family of G-protein-coupled receptors (GPCRs) that are irreversibly activated by proteolytic cleavage of the N terminus, which unmasks a tethered peptide ligand that binds and activates the transmembrane receptor domain, eliciting a cellular cascade in response to inflammatory signals and other stimuli. PARs are implicated in a wide range of diseases, such as cancer and inflammation1,2,3. PARs have been the subject of major pharmaceutical research efforts3 but the discovery of small-molecule antagonists that effectively bind them has proved challenging. The only marketed drug targeting a PAR is vorapaxar4, a selective antagonist of PAR1 used to prevent thrombosis. The structure of PAR1 in complex with vorapaxar has been reported previously5. Despite sequence homology across the PAR isoforms, discovery of PAR2 antagonists has been less successful, although GB88 has been described as a weak antagonist6. Here we report crystal structures of PAR2 in complex with two distinct antagonists and a blocking antibody. The antagonist AZ8838 binds in a fully occluded pocket near the extracellular surface. Functional and binding studies reveal that AZ8838 exhibits slow binding kinetics, which is an attractive feature for a PAR2 antagonist competing against a tethered ligand. Antagonist AZ3451 binds to a remote allosteric site outside the helical bundle. We propose that antagonist binding prevents structural rearrangements required for receptor activation and signalling. We also show that a blocking antibody antigen-binding fragment binds to the extracellular surface of PAR2, preventing access of the tethered ligand to the peptide-binding site. These structures provide a basis for the development of selective PAR2 antagonists for a range of therapeutic uses.
Databáze: OpenAIRE
Externí odkaz: